RT Journal Article SR Electronic T1 Low cost biological lung volume reduction therapy for advanced emphysema JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP P3705 VO 44 IS Suppl 58 A1 Mostafa Bakeer A1 Taha Abd El-Gawad A1 Raed El-Metwaly Ali A1 Ahmed El-Morsi A1 Mohammad El-Badrawy A1 Solafa El-Sharawy YR 2014 UL http://erj.ersjournals.com/content/44/Suppl_58/P3705.abstract AB Background: Bronchoscopic lung volume reduction (BLVR) using biological agents is one of the new alternatives to lung volume reduction surgery.Objectives: To evaluate efficacy and safety of biological BLVR using low cost agents including autologous blood and fibrin glue.Methods: 8 male patients were enrolled and divided into two groups: group A in which autologous blood was used and group B fibrin glue was used. The agents were injected through a triple lumen balloon catheter via fiberoptic bronchoscope. Changes in high resolution CT (HRCT) volumetry, pulmonary function tests, symptoms, and exercise capacity were evaluated at 12-week post procedure as well as for complications.Results: The mean (± SD) age was 57.75 ±10.62 years. In group A at 12-week post procedure there was significant improvement in the mean value of modified medical research council (mMRC) score, 6-min walk distance (6MWD), residual volume / total lung capacity (RV/TLC) ratio, forced expiratory volume in one second /forced vital capacity (FEV1/FVC) ratio, HRCT volumetry (p-value: 0.014, 0.014, 0.008, 0.008, 0.003 respectively). In group B at 12-week post procedure there was significant improvement in the mean value of FEV1/FVC ratio (p-value: 0.012).However, the improvement in the mean value of mMRC score, 6MWD, RV/TLC ratio, HRCT volumetry was not significant (p-value: 0.058, 0.075, 0.164, 0.402 respectively).All patients tolerated the procedure and were discharged 1 day later, except one in group B who developed exacerbation that was controlled by medical therapy.Conclusion: These Preliminary results indicate that BLVR using low cost biological agents was safe, less invasive, less costly and effective in treating advanced emphysema.